This recognition highlights LabVantage’s leadership in visionary innovation, performance, and customer impact, affirming the company’s commitment to delivering cutting-edge, customer-centric solutions across industries.
In this webinar, Andrew Hamilton and Joe Hirano will explore how to detect and remove host cell proteins and other impurities during biologics manufacturing.
Both Pfizer and GSK have shared preliminary data suggesting that their experimental vaccines can protect older adults and newborn infants from the virus.
The Biogen-developed treatment, called lecanemab, appears to have a more clear-cut effect on slowing the disease than the company’s previous Alzheimer’s drug, Aduhelm.
The group’s 7-2 ruling in favor of the therapeutic represents a shift from previous deliberations, in which data on its effectiveness was deemed insufficient.